Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline of degraders, targeting inflammatory diseases and cancers.Access to degrader-antibody conjugates (DACs) platform technology for future discovery engine. Strengthened leadership team designed to support future global growth.Transaction is anticipated to close early in the second quarter of 2026. An updated corporate presentation has been posted to the Gyre and Cullgen websites. SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected...